Search

everythinglearnresearchcommunity

for

Search:↓

Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

Hair loss can occur as a side effect of certain breast cancer treatments, but minoxidil can help regrow hair.

Hedgehog pathway inhibitors could be effective in treating melanoma.

Understanding and managing side effects of hedgehog pathway inhibitors can improve treatment for advanced basal cell carcinoma.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

Honey and bee pollen can help reduce menopausal symptoms in breast cancer patients.

Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.

The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.

Docetaxel is effective against various cancers but mainly causes neutropenia.

Hair growth supplements do not reduce the effectiveness of the breast cancer treatment tamoxifen.

The patient was satisfied with hormone therapy, and her epilepsy remained stable.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.

The combination therapy reduced hirsutism in women with PCOD and was well-tolerated.

Erlotinib can cause persistent excessive hair growth.

PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.

Combining a GnRH agonist with a low-dose oral contraceptive is more effective and safer for treating hirsutism than using either alone.

Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.

The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.

CDK4/6 inhibitors may cause hair loss in breast cancer patients.

EGFR-targeting cancer drugs can cause skin rashes and other side effects.

Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.

Hederagenin shows promise for cancer and inflammation treatment but needs modifications to improve effectiveness.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

EGFR inhibitors can cause unusual localized hair growth.

Sacituzumab govitecan is effective but has side effects like hair loss and diarrhea in treating metastatic triple-negative breast cancer.

Further testing of paclitaxel poliglumex for this cancer treatment is not justified.